An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2-Reference-Cited by-同舟云学术

An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2

Published:1994-11 Issue:3 Volume:28 Page:223-232
ISSN:0162-3109
Container-title:Immunopharmacology
language:en
Short-container-title:Immunopharmacology

Author:

Courtney Lynn P.,Phelps Julia L.,Karavodin Linda M.

Publisher

Elsevier BV

Subject

Pharmacology

Reference39 articles.

1. Bispecific antibodies and targeted cellular cytotoxicity: therapeutic hopes confirmed;Bauer;Vox Sang,1991

2. Autoantibodies to cytokines - friends or foes?;Bendtzen;Immunol. Today,1990

3. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states;Butler;Cancer Res,1988

4. Systemic administration of recombinant human interleukin-2 in mice;Chang;J Biol Res Modif,1984

5. Interleukin 2 (IL 2) administered in vivo: Influence of IL-2 route and timing on T cell growth;Cheever;J Immunol,1985

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering Anticytokine Antibodies for Immune Modulation;The Journal of Immunology;2024-01-15

2. IL-1RA autoantibodies: insights into mechanisms and associated diseases;American Journal of Translational Research;2024

3. Anticorps anti-cytokines : quel impact clinique en pathologie humaine ?;La Revue de Médecine Interne;2022-09

4. Autoantibodies to Tumor Necrosis Factor in Patients with Active Pulmonary Tuberculosis;Frontiers in Bioscience-Landmark;2022-04-20

5. Immunodeficiency and Autoantibodies to Cytokines;The Journal of Applied Laboratory Medicine;2022-01-01